key: cord-0954688-6h5l3ycr
authors: Kittel, M.; Muth, M.; Zahn, I.; Roth, P.; Thiaucourt, M.; Gerhards, C.; Haselmann, V.; Neumaier, M.; Findeisen, P.
title: Clinical evaluation of commercial automated SARS-CoV-2 immunoassays
date: 2020-12-09
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.12.003
sha: 91e277dd0055fde30f0a6949838b23808315d211
doc_id: 954688
cord_uid: 6h5l3ycr

OBJECTIVE: Numerous immunoassays for detecting antibodies directed against SARS-CoV-2 have rapidly been developed and released. Validations of these have been performed with a limited number of samples. The lack of standardization might lead to significantly different results. This study compares ten automated assays from six vendors in terms of sensitivity, specificity, and reproducibility. METHODS: This study compared ten fully automated IAs from the following vendors: Diasorin, Epitope Diagnostics, Euroimmun, Roche, YHLO, and Snibe. The retrospective part of the study included patients with a laboratory-confirmed COVID-19 infection and controls comprised patients with a suspected infection, in whom the disease was excluded. Furthermore, biobanked sera were taken as negative controls (n = 97). The retrospective part involved four classes: 1) laboratory-confirmed COVID-19 infection (n = 183); 1B) suspected COVID-19 infection (n = 167) without qRT-PCR result but positive serological results from at least two different assays, and suspected COVID-19 infection due to a positive serological result from the Roche assay (n = 295); 2) biobanked sera obtained from patients before the emergence of SARS-CoV-2 (n = 97) as negative controls. 2A) probably COVID-19-negative sera with negative serological results from at least two different assays (n = 152). RESULTS: Overall diagnostic sensitivities were: Euroimmun(IgA) 87%; Epitope Diagnostics(IgG) 83%; YHLO(IgG) 77%; Roche(IgM/IgG) 77%; Euroimmun(IgG) 75%; Diasorin(IgG) 53%; Epitope Diagnostics(IgM) 52%; Snibe(IgG) 47%; YHLO(IgM) 35%; Snibe(IgM) 26%. Diagnostic specificities were: YHLO(IgG) 100%; Roche, 100%; Snibe(IgM/IgG) 100%; Diasorin(IgG) 97%; Euroimmun(IgG), 94%; YHLO(IgM) 94%; Euroimmun(IgA) 83%. CONCLUSION: Assays from different vendors vary substantially in terms of their performance. Our findings might facilitate the selection of appropriate serological assays.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly, and the resulting coronavirus disease 2019 (COVID-19) has been declared a public health emergency of international concern by the World Health Organization.

The rapid and accurate diagnosis of the disease is of the utmost importance for subsequent disease management.

While molecular testing with real-time reverse transcriptase polymerase chain reaction (qRT-PCR) has been the primary means for diagnosing acute SARS-CoV-2 infection, serological testing is gaining importance for diagnosing subacute infections or supporting the diagnosis of respiratory insufficiency in cases where the pathogen is no longer detectable in the upper respiratory tract (Cheng et al., 2020 , Loeffelholz and Tang, 2020 , Patel et al., 2020 , Yan et al., 2020 . Specifically, serology can facilitate the diagnosis of SARS-CoV-2 infections when swab specimens were collected incorrectly and the molecular assays might return a false negative (Zhang et al., 2020) . The viral load in swabs decreases in the first week of infection, whereas the concentration of antibodies in serum increases. After approximately eight days of COVID-19, serological testing is more sensitive than viral nucleic acid detection (Guo et al., 2020 , Wolfel et al., 2020 . Specifically, antibodies directed against SARS-CoV-2 can be detected in the serum of approximately 40% of COVID-19 patients as early as seven days after symptom onset, with seroconversion rates rapidly increasing to >90% by Day 14 (Zhao et al., 2020) .

However, serology devices have just received urgent approval from the National

This has resulted in the widespread release of manufacturer-developed laboratory tests that are neither harmonized, standardized, nor thoroughly validated (Farnsworth and Anderson, 2020) . Assays vary in terms of their format, the detected antibody class, and the targeted antigens, and this might lead to poor comparability of results (Okba et al., 2020 . A comprehensive overview of currently available serological test systems can be found on the website of the Johns Hopkins Center for Health Security (health, 2020).

The aim of this study was to compare the diagnostic sensitivity and specificity of commercially available SARS-CoV-2 immunoassays. The selection of these tests was based on availability in our laboratory at the time of testing.

J o u r n a l P r e -p r o o f Serum specimens Serum tubes (7.5 ml Gel-Monovette; Sarstedt, Nümbrecht, Germany) were used for blood sampling. Specimens were centrifuged at 20°C for 10 minutes at 2500 g. Serum was collected and the samples were analyzed as soon as possible. If the analyses were delayed, samples were aliquoted and stored between 2°C and 8°C for a maximum of three days. If they had to be stored for longer than three days, the serum samples were cryopreserved at -20°C.

To assess the stability of the analytes in serum, five freshly obtained serum samples were analyzed with the Roche IgM/IgG assay under the following preanalytical conditions: 1) measurements were performed immediately with the freshly obtained specimens; 2) one aliquot of any specimen was stored at -20°C prior to delayed measurements; 3) a second aliquot of any specimen was left at room temperature (20-25°C) for seven days prior to freezing at -20°C. All frozen aliquots were thawed and measured independently on Day 7. Measurements were performed with the Roche 8 stored at -20°C until further use. The following four classes were defined: 1) COVID-19 cases confirmed by qRT-PCR (n=183); 1B) probably COVID-19-positive sera with no qRT-PCR result but positive serological results from at least two or more different assays (n=167), and samples with a suspected COVID-19 infection due to a positive serological result from the Roche IgM/IgG assay (n=295); 2) prepandemic sera (n=97); 2A) probably COVID-19-negative sera with negative serological results from at least two or more different assays (n=152). Due to the use of leftover material, not all samples were passed through all platforms.

This part of the study was performed on patient material collected previously for diagnostic purposes (secondary use). The anonymized patient material was used in Table 1 . The study was approved by the Institutional Review Board, and written consent was obtained from each subject before sample collection and analysis.

The SARS-CoV-2 serology was routinely performed on an iFLASH 1800 using the IgM and IgG assays from Shenzhen YHLO Biotech. In addition, alternative serological assays from six suppliers listed in Table 2 were performed in parallel. All serum antibody tests were performed with fully automated analyzers according to the J o u r n a l P r e -p r o o f estimate imprecision, reproducibility, linearity, and limit of detection (LOD). These validation steps were carried out using Abacus 2.0 (LABanalytics GmbH, Germany).

For normalization of data, the Z-score was calculatedi.e., the difference between the measured value and the assigned value, corrected for the variability (Coucke and Soumali, 2017) .

The intra-assay variabilities of the SARS-CoV-2 IgM and IgG tests from Shenzhen YHLO Biotech and Roche were determined five times on five consecutive days in line with the EP15-A3 protocol from the Clinical and Laboratory Standards Institute. The inter-assay variabilities were determined by a single measurement of a negative and a positive control over 15 days. Figure 1 shows the precision data for Shenzhen YHLO Biotech's IgM and IgG tests. Reproducibility was high, as coefficients of variation (CV) for all positive specimens were below 8%.

Preanalytical stability was high and no statistically significant deviation between results from initial and delayed measurements could be detected. The CV for all measurements was 4.8%, which is within the range of the abovementioned reproducibility.

Positive serum specimens with titers at least 10 times above the cut off value were diluted 1:1 stepwise. The dilution series were performed for the Shenzhen YHLO Biotech IgG assay and for the Roche IgG/IgM assay. Both assays were not linear and saturation was observed for higher concentrations (Supplemental Figure 1 ). The limit of blank (LOB) for the SARS-CoV-2 IgM test was 0.192 AU/mL, and 0.05 AU/mL for the IgG test. The limit of detection (LOD) for the SARS-CoV-2 IgM test was 0.36 AU/mL, and 0.145 AU/mL for the IgG test. The ECLIA test from Roche yielded an LOD of 0.068 COI and a limit of quantification (LOQ) of 0.082 COI.

The SARS-CoV-2 IgM and IgG assays from Shenzhen YHLO Biotech (cut-off value:

10 AU/mL) and Roche Diagnostics (cut-off value: 1 COI/QE) were compared. The data were standardized using the Z-score calculation with Log (1) as cut-off value (Coucke and Soumali, 2017) . QRT-PCR-confirmed COVID-19 sera (n=59) and prepandemic control sera (n=50) were used.

The Shenzhen YHLO Biotech IgG test correctly identified more COVID-19 cases as positive than the Roche IgM/IgG test ( Figure 2 ). However, in subsequent analyses (see section "Comparison of the two superior tests"), samples were identified that were positive with the Roche IgM/IgG test but negative with the Shenzhen YHLO Biotech IgG test. The Shenzhen YHLO Biotech IgM assay showed the lowest performance.

The control sera were correctly identified as negative by both IgG tests. Worthy of note is the large interquartile distance of the Roche IgM/IgG assay among the COVID-19 positive sera, and the particularly small interquartile distance among the negative sera. Sensitivity Figure 3 shows the sensitivity of SARS-CoV-2 antibody tests from six manufacturers.

Serum specimens from qRT-PCR-confirmed patients (Class 1) IgA had 83%. Due to their low sensitivity performance and the limited amount of sample metaerial, the assays from Epitope Diagnostics were not further tested for specificity.

The diagnostic power of all IAs listed in Table 2 Table 3 .

Identical specimens of proven (Class 1) and probable (Class 2) COVID-19 patients, as well as controls from prepandemic patients (Class 2) and SARS-CoV-2-negative patients (Class 2A) were tested in parallel with all IAs listed in Table 1 . The highest concordance was observed between the Shenzhen YHLO IgG assay and the Roche IgM/IgG assay, with 83%, 94%, 100%, and 100% for classes 1, 1B, 2, and 2A respectively (Supplemental Figure 2) . 

Discussion Serology testing for SARS-CoV-2 is becoming increasingly interesting as a way of better quantifying the number of COVID-19 infections. Specifically, patients who had a subclinical infection or were perhaps even asymptomatic often lack results from molecular diagnostic assays. Accordingly, the combination of molecular and serological assays can greatly improve the diagnostic efficacy (Krammer and Simon, 2020 , Lou et al., 2020 , Winter and Hegde, 2020 . Serological testing is an integral component of a testing algorithm that has been proposed by the Infectious Diseases Society of America (Lu et al., 2020) .

However, due to their rapid introduction, the available SARS-CoV-2 assays have not been thoroughly validated. Furthermore, different immunoassays vary in terms of format, detected antibody class, targeted antigen, and acceptable specimen types (Bryant et al., 2020 , Okba et al., 2020 . Therefore, results from different assays are not necessarily congruent, as the respective diagnostic specificities and sensitivities vary (Younes et al., 2020) .

Over the last month several method comparisons have been published to date. Some authors compared a limited number of tests comprising not more than two immunoassays (Kohmer et al., 2020b , Montesinos et al., 2020 , Nicol et al., 2020 . In contrast, Lassaunière et al. (Lassaunière et al., 2020 ) evaluated nine commercial SARS-CoV-2 immunoassays. However, the majority of these were point-of-care tests and only two vendors (Wantai and Euroimmun) offered automated test formats.

Plebani et al. (Plebani et al., 2020) compared the reliability of three chemiluminescent immunoassays (CLIA) and two enzyme-linked immunosorbent assays (ELISA).

However, the focus of their work was the definition of optimized thresholds that might improve the negative likelihood ratio and reduce the false positives that can hamper any screening approach in an asymptomatic population (Plebani et al., 2020) . A recent study from Weidner et al. (Weidner et al., 2020) focused on a quantitative correlation between different commercial assays including automated platforms from Euroimmun, Wantai, Roche, and Diasorin, However, the study only included sera from SARS-CoV-2 convalescent patients, and no COVID-19-negative controls. In a further study, Kohmer et al. (Kohmer et al., 2020a) compared the performance of six automated immunoassays (from Abbott, Roche, Diasorin, Virclia, Euroimmun, and Virotech).

However, the analyses were restricted to IgG and total antibodies, and only limited numbers of COVID-19 patients (n=45) and non-COVID-19 patients (n=37) were analyzed. In the most recent study, Krüttgen et al. (Kruttgen et al., 2020) compared four commercial assays. Again, the study's shortcoming is the limited number of sera from patients who tested positive or negative by SARS-CoV-2 PCR (n=75). The issue of small sample size has been highlighted by a systematic review and meta-analysis (Lisboa .

Here, we present data from 10 immunoassays comprising IgA, IgM, IgG, and combined IgG/IgM tests from six vendors (Diasorin, Epitope Diagnostics, Euroimmun, Roche, Shenzhen YHLO Biotech, and Snibe). Altogether, the study included over 900 serum specimens (n=904) from patients with proven (n=193) and probable (n=167) COVID-19 infection, and controls from prepandemic patients (n=97) and probable SARS-CoV-2-negative patients (n=152). Specimens with SARS-CoV-2-positive results from the Roche IgG/IgM test (n=295) were re-analyzed with the Shenzhen YHLO Biotech IgG assay.

As expected, assay performance was markedly different, with AUROC values ranging from 0.66 (Snibe IgM) to 0.97 (Shenzhen YHLO Biotech IgG). The best concordance was observed between the Shenzhen YHLO Biotech IgG and the Roche IgG/IgM tests.

The comparison of the Shenzhen YHLO Biotech IgG assay and the Roche IgG/IgM assay revealed a small subset of specimens that are positive in only one of the two assays. This indicates an individual immune response to SARS-CoV-2 and the influence of the assays used (Kohmer et al., 2020a) . Antibodies that are exclusively detected by the N-protein-based Roche assay (Table 2 ) might not have neutralizing capacity. In contrast, antibodies directed against the S protein can interfere with the virus's ability to bind to the ACE receptor of the host cell and will most likely have neutralizing capacity. Further analyses are needed to decipher the humoral immune response (Kreer et al., 2020) .

The IgG-positive rate was consistently higher than the IgM-positive rate, and this phenomenon was also observed in another study (Zhang et al., 2020) . The clinical value of IgM for early diagnosis of COVID-19 is currently unclear. SARS-CoV-2specific IgM does not always appear before its IgG counterpart. Some studies have reported the detection of SARS-CoV-2-specific IgG even before IgM (Thevarajan et al., 2020 , Zhao et al., 2020 . However, even if IgM sensitivity is superior in a few cases, the low specificity of IgM antibodies is an obstacle to clear interpretations of test results. Specifically, a low prevalence of COVID-19 patients leads to significant numbers of false positives, not only for IgM assays but also for IgG assays with high specificity (Lisboa Bastos Mayara et al., 2020) . Furthermore, the possibility of false negative results and the phenomenon of missing seroconversion will have to be discussed. We observed the repeated absence of SARS-CoV-2-specific IgG and IgM antibodies for one patient as long as nine weeks after a positive qRT-J o u r n a l P r e -p r o o f measurements with the Roche IgG/IgM assay Recently, a multiplexed assay format for simultaneous quantitation of IgG, IgM, and IgA immunoglobulins against four SARS-CoV-2 targets has been described (Norman et al., 2020) . It results in the monitoring of 12 antibody isotype-viral protein interactions, and this high-resolution profile of the immune response might be needed to resolve rare cases of missing seroconversion.

Another explanation for this phenomenon might be a false-positive test result. These cases are rare but have been reported in literature (fda.gov, 2020 (fda.gov, , Surkova et al., 2020 .

This study has several limitations. Firstly, clinical data for most patients were not available because all of the specimens from the MVZ Laboratory in Heidelberg were anonymized. Secondly, the humoral immune response might be affected by the severity of COVID-19 infections or by various comorbidities (Long et al., 2020 , Zhao et al., 2020 . Furthermore, the serological diagnosis of COVID-19 is strongly influenced by the time of blood draw, as seroconversion is time-dependent. In our study, the date of positive qRT-PCR was taken as the reference timepoint. However, as virus elimination and positive qRT-PCR can be prolonged (Guo et al., 2020 , Wolfel et al., 2020 , the onset of symptoms might have been a more accurate reference point, unfortunately this was only available for a minor fraction of the samples. Finally, due to the use of leftover material, not all samples were passed through all platforms in our retrospective study.

A further limitation of the study is the collective 2B. Here the Roche assay was used as a surrogate marker of an experienced SARS-CoV-2 infection. On the one hand, this risks to positively bias the study results in favor of the Roche assay, but had to be chosen due to the study design. Laboratories, who aren´t directly integrated into a test was chosen because the manufacturer could demonstrate a specificity collective of almost 5000 patients at that time.

These limitations indicate the need for large, prospective, and multicenter studies to elucidate the advantages and disadvantages of serological testing.

The authors declare that they have no known competing financial interests or personal relationships it could have appeared to influence the work reported in this paper. J o u r n a l P r e -p r o o f Table 3 . All study projects were carried out without funding.

None of the authors has indicated a conflict of interest.

J o u r n a l P r e -p r o o f

Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward

Die (Weiter-)Verwendung von menschlichen Körpermaterialien für Zwecke medizinischer Forschung

Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative Review

Demystifying EQA statistics and reports

SARS-CoV-2 Serology: Much Hype, Little Data

False Positive Results with BD SARS-CoV-2 Reagents for the BD Max System -Letter to Clinical Laboratory Staff and Health Care Providers

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays

Clinical performance of different SARS-CoV-2 IgG antibody tests

Serology assays to manage COVID-19

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG

Evaluation of nine commercial SARS-CoV-2 immunoassays

Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis

Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis

A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients

Laboratory diagnosis of emerging human coronavirus infections -the state of the art

Antibody responses to SARS-CoV-2 in patients with COVID-19

Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset

An Evolving Approach to the Laboratory Assessment of COVID-19

Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies

Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech)

Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

Report from the American Society for Microbiology COVID-19 International Summit

Diagnostic performances and thresholds: The key to harmonization in serological SARS-CoV-2 assays?

False-positive COVID-19 results: hidden problems and costs. The Lancet Respiratory Medicine

Laboratory Diagnosis of COVID-19: Current Issues and Challenges

The Role of Antibody Testing for SARS-CoV-2: Is There One?

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays

The important role of serology for COVID-19 control

Virological assessment of hospitalized patients with COVID-2019

Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures

Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019